METHODS OF DIAGNOSING, DETERMINING THE PROGRESSION OF, AND TREATING A PROSTATE CANCER
Methods for detecting a prostate cancer in a subject comprise detecting a marker selected from an endosomal associated marker and/or a lysosomal associated marker from the subject.
1 . A method of diagnosing and treating a prostate cancer in a subject, the method comprising:
detecting APPL1 and SCD1 in a sample obtained from the subject;
determining the level of APPL1 and the level of SCD1 in the sample;
comparing the level of APPL1 to the level of SCD1 in the sample to the level of APPL1 to SCD1 in a non-malignant tissue to obtain an indication of prostate cancer in the subject, wherein an increased level of APPL1 to SCD1 in the sample as compared to the non-malignant tissue is indicative of prostate cancer in the subject; and
subjecting the subject to any of:
(i) active surveillance;
(ii) surgical prostatectomy;
(iii) an effective amount of a therapeutic agent; or
(iv) androgen deprivation therapy (ADT).
2 . The method according to claim 1 , wherein the subject is administered with ADT before, during and after radiation therapy.
3 . The method according to claim 1 , wherein the detecting is visual detecting.
4 . The method according to claim 1 , wherein the determining of levels of APPL1 and the level of SCD1 is visual determining.
5 . The method according to claim 4 , which comprises detecting a further marker which is selected from one or more of SORT1, M6PR (CD-MPR), IGF2R (CI-MPR), PDCD61P (ALIX), and MYO1B (Myosin 1B).
6 . The method according to claim 4 , wherein the detecting step comprises contacting the sample with a composition that comprises a mono or polyclonal antibody that binds to SCD1 and a mono- or polyclonal antibody that binds to SORT1.
7 . The method according to claim 1 , wherein the detecting step comprises contacting the sample with a composition that comprises a mono or polyclonal antibody that binds to APPL1 and a mono- or polyclonal antibody that binds to SCD1.
8 . A method of diagnosing and treating a prostate cancer in a subject, the method comprising:
detecting SCD1 and SORT1 in a sample obtained from the subject;
determining the level of SCD1 to the level of SORT1 in the sample;
comparing the level of SCD1 to the level of SORT1 in the sample to the level of SCD1 to SORT1 in a non-malignant tissue to obtain an indication of prostate cancer in the subject, wherein an increased level of SDC1 to SORT1 in the sample as compared to the non-malignant tissue is indicative of prostate cancer in the subject; and
subjecting the subject to any of:
(i) active surveillance;
(ii) surgical prostatectomy;
(iii) an effective amount of a therapeutic agent;
(iv) androgen deprivation therapy (ADT); or
(v) radiation therapy.
9 . The method according to claim 8 , wherein the subject is administered with ADT before, during and after radiation therapy.
10 . The method according to claim 8 , wherein the detecting is visual detecting.
11 . The method according to claim 8 , wherein the determining of levels of APPL1 and the level of SCD1 is visual determining.
12 . The method according to claim 8 , which comprises detecting a further marker which is selected from one or more of SORT1, M6PR (CD-MPR), IGF2R (CI-MPR), PDCD61P (ALIX), and MYO1B (Myosin 1B).
13 . A method of determining the progression and treating prostate cancer in a subject, the method comprising:
visually detecting APPL1 and SCD1 in a sample obtained from the subject;
visually determining the level of APPL1 to the level of SCD1 in the sample;
visually comparing the level of APPL1 to the level of the SCD1 in the sample to the level of APPL1 to the level of SCD1 in a non-malignant tissue, wherein an amount of increase in the level of APPL1 to SCD1 in the sample is an indication of the progression of prostate cancer in the subject; and
administering to the subject having prostate cancer any of: active surveillance, surgical prostatectomy, radiation therapy, or ADT in response to the indication of progression.
14 . The method according to claim 13 , wherein the ratio of the level of the APPL1 to SDC1 is indicative of a reduced relapse rate and/or increased survival rate.
15 . The method according to claim 13 , wherein the detecting step comprises contacting the sample with a composition that comprises a mono- or polyclonal antibody that binds to APPL1 and a mono or polyclonal antibody that binds to SDC1.
16 . The method according to claim 13 , wherein the method further comprises detecting one or more of an early endosomal marker, a late endosomal marker, a marker associated with endosomal biogenesis, a marker associated with endosomal trafficking and a marker associated with endosomal recycling, and wherein the further marker is selected from one or more of SORT1, M6PR (CD-MPR), IGF2R (CI-MPR), PDCD61P (ALIX), and MYO1B (Myosin 1B).
17 . A method of determining the progression and treating prostate cancer in a subject, the method comprising:
visually detecting SCD1 and SORT1 in a sample obtained from the subject;
visually determining the ratio of the level of SCD1 to the level of SORT1 in the sample;
visually comparing the ratio of the level of SCD1 to the level of the SORT1 in the sample to the level of SCD1 to the level of SORT1 in a non-malignant tissue to, wherein an amount of increase in the level of SCD1 to SORT1 in the sample is an indication of the progression of prostate cancer in the subject; and
administering to the subject having prostate cancer any of active surveillance, surgical prostatectomy, radiation therapy, or ADT in response to the indication of progression.
18 . The method according to claim 17 , wherein the ratio of the level of SCD1 to SORT1 is indicative of an increased relapse rate and/or decreased survival rate.
19 . The method according to claim 17 , wherein the detecting step comprises contacting the sample with a composition that comprises a mono or polyclonal antibody that binds to SCD1 and a mono or polyclonal antibody that binds to SORT1.
20 . The method according to claim 14 , wherein the method further comprises detecting one or more of an early endosomal marker, a late endosomal marker, a marker associated with endosomal biogenesis, a marker associated with endosomal trafficking and a marker associated with endosomal recycling, and wherein the further marker is selected from one or more of APPL1, M6PR (CD-MPR), IGF2R (CI-MPR), PDCD61P (ALIX), and MYO1B (Myosin 1B).